Challenges to genetic testing for germline mutations associated with breast cancer among African Americans Authors
Cancer is a genomic disease in that gene alterations drive the cellular proliferation and immune surveillance abnormalities that facilitate malignant initiation and progression. Hereditary genetic factors play a vital role that underlies cancer risk and prognosis. The National Comprehensive Cancer Network (NCCN) guidelines recommend genetic testing for individuals with a personal history of breast cancer with specific features ( ≤50 years old, or any age to aid in systemic treatment decisions in the adjuvant or metastatic setting, specific histologies, male breast cancer, and Ashkenazi Jewish ancestry). (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 31, 2024 Category: Cancer & Oncology Authors: S. Kamaraju, M. Conroy, A. Harris, M. Georgen, H. Min, P. Miracle, R. Kurzrock Tags: Hot Topic Source Type: research
A conceptual framework for cautious escalation of anticancer treatment: how to optimize overall benefit and obviate the need for de-escalation trials
In clinical cancer research investigating new therapies, it is of utmost importance to characterize the balance between treatment burden and benefit and to determine the optimal efficacy threshold above which additive toxicity would not be counterbalanced by net additive benefit. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 30, 2024 Category: Cancer & Oncology Authors: I. Pourmir, Hk. Van Halteren, R. Elaidi, D. Trapani, F. Strasser, G. Vreugdenhil, M. Clarke Tags: Controversy Source Type: research
How To Deal With Renal Toxicities From Immune-Based Combination Treatments In Metastatic Renal Cell Carcinoma. A Nephrological Consultation For Oncologists
Every year, more than 430.000 kidney cancer cases are diagnosed worldwide, leading to approximately 180.000 deaths [1]. Renal cell carcinoma (RCC) represents the vast majority of the cancers of the kidney, being histologically represented by a number of different entities, including clear cell RCC (ccRCC) (70%), papillary RCC (10%), and chromophobe RCC (5%)[2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 22, 2024 Category: Cancer & Oncology Authors: Tucci Marcello, Cosmai Laura, Pirovano Marta, Campisi Ilaria, Re Sart ò Giulia Vanessa, Porta Camillo, Gallieni Maurizio, Piergiorgio Messa Tags: Complications of Treatment Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 19, 2024 Category: Cancer & Oncology Source Type: research
Navigating between Scylla and Charybdis: A roadmap to do better than pola-RCHP in DLBCL
Scylla and Charybdis were two immortal creatures in Greek mythology who beset the narrow waters traversed by the hero Odysseus in his wanderings described in Homer ’s Odyssey. Odysseus once navigated between these two life-threatening evils within an arrowshot of each other. On one side, there was the six-headed sea monster called Scylla. On the other side, there was the monstrous whirlpool called Charybdis. Odysseus, trying to avoid losing his entire ship t o Charybdis, navigated too close to Scylla, losing some of his crew but safeguarding the ship. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 16, 2024 Category: Cancer & Oncology Authors: Javier Munoz, Anagha Deshpande, Lisa Rimsza, Grzegorz S. Nowakowski, Razelle Kurzrock Tags: Anti-tumour Treatment Source Type: research
Optimizing Lung Cancer Radiation Therapy: A systematic review of Multifactorial Risk Assessment for Radiation-Induced Lung Toxicity
Lung cancer remains a global health challenge, accounting for over two million new cases annually and one of the highest mortality rates among all cancers in 2020 [1]. Non-small-cell lung cancer (NSCLC) represents approximately 80% of total cases. In 2010, between 15% and 25% of lung cancer patients presented with inoperable tumors at diagnosis, with concurrent chemoradiotherapy (CCRT) using platinum as the standard of care for this population facing a NSCLC or a small-cell lung cancer (SCLC); both taking benefit from this therapeutic [2,3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 12, 2024 Category: Cancer & Oncology Authors: Rayan Bensenane, Sylvie Helfre, Kim Cao, Matthieu Carton, Laurence Champion, Nicolas Girard, Matthieu Glorion, Thibaut Vieira, Waisse Waissi, Gilles Crehange, Arnaud Beddok Tags: Anti-tumour Treatment Source Type: research
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: a systematic review
Background (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - January 12, 2024 Category: Cancer & Oncology Authors: Davide Ciardiello, Gianluca Mauri, Andrea Sartore-Bianchi, Salvatore Siena, Maria Giulia Zampino, Nicola Fazio, Andres Cervantes Tags: Systematic or Meta-analysis Studies Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 29, 2023 Category: Cancer & Oncology Source Type: research
Desmoid-type fibromatosis: Current Therapeutic Strategies and Future Perspectives
Desmoid tumors (DT), also known as aggressive fibromatosis or deep fibromatosis are rare mesenchymal neoplasms that are considered locally invasive with significant morbidity and mortality. [1 –2] DT are extremely rare, with a reported incidence of 2-4 per million population and account for only 0.03% of all diagnosed neoplasms. [3–4] They are more frequent among female patients and most commonly develop in patients between the ages of 15 and 60 years. [5] They most commonly occur in the abdominal wall, mesentery or the extremities. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 25, 2023 Category: Cancer & Oncology Authors: Rebecca IBRAHIM, Tarek ASSI, Rita Khoury, Carine NGO, Matthieu Faron, Benjamin Verret, Antonin L évy, Charles Honoré, Clémence Hénon, Cécile Le Péchoux, Ratislav Bahleda, Axel Le Cesne Tags: Anti-tumour Treatment Source Type: research
Neoadjuvant chemotherapy for early-stage colon cancer
Colorectal cancer (CRC) is the 3rd most commonly diagnosed tumour and the 2nd leading cause of cancer-related deaths worldwide, with colonic tumours accounting for about two thirds of all these cases (1). Approximately 80% of patients are diagnosed with early-stage disease (2). In this setting, surgical resection is the mainstay of treatment, with 5-year survival rates of approximately 99% for stage I, 80% for stage II, and 50% for stage III cancers (3,4). (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 22, 2023 Category: Cancer & Oncology Authors: Alessandro Audisio, Roberta Fazio, Valentina Dapr à, Irene Assaf, Alain Hendlis, Francesco Sclafani Tags: Hot Topic Source Type: research
Histology independent drug development – is this the future for cancer drugs?
This White Paper has been developed following the Cancer Drug Development Forum (CDDF) ’s ‘Histology independent drug development – is this the future for cancer drugs?’ workshop, which took place on 14-15th November, 2022, in Amsterdam. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 22, 2023 Category: Cancer & Oncology Authors: Lucinda Billingham, Lynn Brown, Theodor Framke, Alastair Greystoke, Eivind Hovig, Siddhartha Mathur, Philippe Page, Elias Pean, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Richardus Vonk, Sacha Wissink, Hilke Zander, Ruth Plummer Tags: Hot Topic Source Type: research
The State of the Art of EGFR exon 20 insertions in non-small cell lung cancer: diagnosis and future perspectives
Lung cancer (LC) is the leading cause of cancer-related mortality worldwide, and, although smoking is the most frequent cause of LC, 10-15% of all LCs are diagnosed in never-smokers.[1] Treatment of actionable mutations in about 60% of non-small cell lung cancer (NSCLC) marked the era of precision medicine with the use of a whole generation of targeted therapies that have dramatically improved patient prognosis.[2] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 19, 2023 Category: Cancer & Oncology Authors: Miriam Dorta-Su árez, Maria de Miguel, Oscar Amor-Carro, José Miguel Calderón, MCarmen González-Ortega, Delvys Rodríguez-Abreu Tags: Tumour Review Source Type: research
Phase to Phase: Navigating Drug Combinations with Hypomethylating Agents in Higher-risk MDS Trials for Optimal Outcomes
Management of myelodysplastic neoplasms (MDS) is a multifaceted challenge that requires a personalized approach, aimed at enhancing both the quality of life and longevity for each patient. Considering the broad heterogeneity in clinical outcomes, it is crucial to adopt a personalized, patient-centered treatment approach and for assessment of therapy success [1]. Risk stratification with the Revised International Prognostic Scoring System (IPSS-R) classifies patients into two primary categories, lower-risk MDS (LR MDS) and higher-risk MDS (HR MDS) [2 –3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 18, 2023 Category: Cancer & Oncology Authors: Almuth Maria Anni Merz, Marie Sebert, Jan Sonntag, Anne Sophie Kubasch, Uwe Platzbecker, Lionel Ad ès Tags: Tumour Review Source Type: research
Breaking barriers in Triple Negative Breast Cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)
Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) on tumor cells. It accounts for 15-20% of newly diagnosed breast cancer (BC) cases and is distinguished by the least favorable prognosis among BC subtypes, along with a long-standing paucity of effective therapeutic options.[1,2] In the past few years, research breakthroughs have brought to light the significance of the TNBC microenvironment heterogeneity, revealing a dynamic relationship with cancer cell features and emphasizing the need for a...
Source: Cancer Treatment Reviews - December 14, 2023 Category: Cancer & Oncology Authors: Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fa Tags: New Drugs Source Type: research
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
Liposarcomas (LPS) are rare mesenchymal neoplasms that arise from lipocytes in soft tissues. LPS account for approximately 15% to 20% of all soft tissue sarcomas in adults [1,2]. LPS may arise in any anatomic site; the most common locations are the retroperitoneum and extremities [3,4]. In 2016, the incidence of liposarcoma in the United States was approximately 1 per 100,000 person-years [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 8, 2023 Category: Cancer & Oncology Authors: Neeta Somaiah, William Tap Tags: Tumour Review Source Type: research
